Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.

Jai-Shin LiuWei-Kai FangShan-Min YangMeng-Chen WuTsan-Jan ChenChih-Ming ChenTung-Yueh LinKai-Lun LiuChien-Ming WuYun-Ching ChenChih-Pin ChuuLing-Yu WangHsing-Pang HsiehHsing-Jien KungWen-Ching Wang

Published in: Journal of biomedical science (2022)

These results suggest that myricetin is a pan-KDM4 inhibitor and exhibited potent cell cytotoxicity toward CRPC cells. Importantly, the combination of PLGA-encapsulated myricetin with enzalutamide is potentially effective for CRPC.

Keyphrases

drug delivery
induced apoptosis
prostate cancer
cell cycle arrest
single cell
cell therapy
cell death
drug release
mesenchymal stem cells
cell proliferation
bone marrow
bone regeneration